MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
17.25
+0.09 (+0.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close17.16
Open17.29
Bid0.00 x 3100
Ask0.00 x 1400
Day's range16.85 - 17.49
52-week range12.75 - 23.11
Volume6,244,526
Avg. volume7,960,395
Market cap8.917B
Beta (5Y monthly)1.55
PE ratio (TTM)143.75
EPS (TTM)0.12
Earnings date27 Jul 2020 - 31 Jul 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Jun 2007
1y target est22.07
  • Business Wire

    Delaware Enhanced Global Dividend and Income Fund Appoints Allan Saustrup Jensen as Co-Manager

    Today, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a New York Stock Exchange–listed closed-end fund trading under the symbol "DEX," announced that, effective May 19, 2020, Allan Saustrup Jensen will be appointed as co-manager for the Fund. Mr. Jensen will join Damon J. Andres, Åsa Annerstedt, Wayne A. Anglace, Adam H. Brown, Liu-Er Chen, Craig C. Dembek, Roger A. Early, Chris Gowlland, Jens Hansen, Claus Juul, Nikhil G. Lalvani, Paul A. Matlack, John P. McCarthy, Klaus Petersen, and Babak (Bob) Zenouzi in making day-to-day investment decisions for the Fund.

  • Better Buy: Pfizer vs. Bristol Myers Squibb
    Motley Fool

    Better Buy: Pfizer vs. Bristol Myers Squibb

    Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.

  • Markets Set Out on Long Journey to Recovery: 4 ROE Picks
    Zacks

    Markets Set Out on Long Journey to Recovery: 4 ROE Picks

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally
    Motley Fool

    Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally

    Mylan (NASDAQ: MYL) announced on Tuesday that it has entered into a global partnership with Gilead Sciences (NASDAQ: GILD) to manufacture and distribute remdesivir in 127 low- and middle-income countries as a treatment for COVID-19. Because of the urgent nature of the pandemic, Gilead has indicated its desire to make remdesivir widely available as quickly as possible, and partnering with Mylan will help it accomplish that goal. The pharmaceutical companies have worked together for 15 years in their efforts to fight other infectious diseases including HIV and hepatitis C. Remdesivir is the 10th drug licensed by Gilead to Mylan.

  • Is Mylan (MYL) Stock Undervalued Right Now?
    Zacks

    Is Mylan (MYL) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Mylan N.V. (MYL) Q1 2020 Earnings Call Transcript
    Motley Fool

    Mylan N.V. (MYL) Q1 2020 Earnings Call Transcript

    MYL earnings call for the period ending March 31, 2020.

  • What's Behind Mylan's Mixed Q1 Results
    Motley Fool

    What's Behind Mylan's Mixed Q1 Results

    You might say that Mylan (NASDAQ: MYL) is a company in waiting. At some point over the next few months, its merger with Pfizer's Upjohn will close. Mylan will be no more; a new company named Viatris will be created from the merger.

  • Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling
    Zacks

    Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling

    Mylan (MYL) beats on Q1 earnings but misses on sales.

  • Mylan (MYL) Q1 Earnings Top Estimates
    Zacks

    Mylan (MYL) Q1 Earnings Top Estimates

    Mylan (MYL) delivered earnings and revenue surprises of 2.27% and -2.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Retail sales, Fed Chair Jerome Powell speaks: What to know in the week ahead
    Yahoo Finance

    Retail sales, Fed Chair Jerome Powell speaks: What to know in the week ahead

    COVID-19 and its impact on the U.S. economy will continue to take centerstage in the week ahead.

  • How Low Will Pfizer's Dividend Go After the Mylan-Upjohn Deal?
    Motley Fool

    How Low Will Pfizer's Dividend Go After the Mylan-Upjohn Deal?

    Pfizer (NYSE: PFE) will lower its dividend payout at some point later this year for a straightforward reason. The pharma giant plans to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL). The transaction will form a new entity that will be known as Viatris.

  • Revance Therapeutics (RVNC) Q1 2020 Earnings Call Transcript
    Motley Fool

    Revance Therapeutics (RVNC) Q1 2020 Earnings Call Transcript

    Joining us on the call today from Revance is President and Chief Executive Officer Mark Foley, Chief Financial Officer Toby Schilke, Chief Operating Officer and President of R&D and Product Operations Dr. Abhay Joshi and Chief Commercial Officer of Aesthetics and Therapeutics Dustin Sjuts. Earlier today, Revance released financial results for the first quarter ended March 31, 2020.

  • Is a Surprise Coming for Mylan (MYL) This Earnings Season?
    Zacks

    Is a Surprise Coming for Mylan (MYL) This Earnings Season?

    Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
    Zacks

    Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates

    Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

  • Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?
    Zacks

    Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?

    Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.

  • Reuters

    EU clears Mylan's purchase of Pfizer's Upjohn unit with conditions

    The European Commission said on Wednesday it had approved generic drugmaker Mylan NV's <MYL.O> planned purchase of Pfizer's <PFE.N> off-patient branded drugs business Upjohn, subject to conditions. The Commission, which oversees competition policy in the European Union, said its investigation had focused on genericised medicines, which are sold to pharmacies and hospitals, with overlaps in a number of fields. Mylan and Upjohn have offered to divest Mylan's certain generic medicines across 20 countries in the European Economic Area and the United Kingdom, the Commission said.

  • Why Mylan (MYL) is Poised to Beat Earnings Estimates Again
    Zacks

    Why Mylan (MYL) is Poised to Beat Earnings Estimates Again

    Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Mylan's Robert Coury back as executive chairman
    Reuters

    Mylan's Robert Coury back as executive chairman

    Coury had previously served as executive chairman between 2012 and 2016. Mylan is now banking on that experience to help it through a critical time for drugmakers and corporate America in general, as the global economy heads for what is likely to be a deep recession. "Given the unprecedented current operating environment due to the COVID-19 pandemic ... the Mylan Board has determined that it is in the best interests of the company for Mr. Coury to assume this position effective immediately," Mylan said in a statement.

  • Novartis Terminates Sale of Sandoz Dermatology Business
    Zacks

    Novartis Terminates Sale of Sandoz Dermatology Business

    Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.

  • How Much Are Mylan N.V. (NASDAQ:MYL) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Mylan N.V. (NASDAQ:MYL) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma
    Zacks

    Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma

    Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.

  • Mylan offers concessions to address EU concerns about Pfizer deal
    Reuters

    Mylan offers concessions to address EU concerns about Pfizer deal

    Generic drugmaker Mylan NV <MYL.O> has offered concessions to address European Union antitrust concerns about its bid for Pfizer's <PFE.N> off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday. U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines. The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27.

  • Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound?
    Zacks

    Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak
    Reuters

    Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

    Due to restrictions on large gatherings, the general meeting of shareholders to approve certain matters for the deal to go through has been postponed to June 30, Mylan said. There were no other changes to previously announced terms or plans pertaining to the deal, previously expected to close in mid-2020, the companies said. The merger, which will bring blockbuster treatments Viagra and Lipitor from Pfizer under one umbrella with Mylan's EpiPen, is part of years-long effort by Pfizer to split into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more